GSK pledges $30bn US investment as UK's pharma woes deepen

GSK commits $30bn US investment as UK's pharma issues deepen, supporting research and manufacturing in the next five years. The investment aims to develop new factories, AI, and research labs in the US, coinciding with President Trump's UK visit. Prime Minister Starmer praises the collaboration, highlighting job creation and promoting drug development through this alliance between the two countries.